• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:张丽,王艳青,王艳,刘建荣,张晓敏.替尔泊肽通过FOXO1/CCND1信号通路抑制银屑病HaCaT细胞增殖及炎症反应的机制[J].药学研究,2026,45(9):983-989,1012[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 222次   下载 212次 本文二维码信息
码上扫一扫!
替尔泊肽通过FOXO1/CCND1信号通路抑制银屑病HaCaT细胞增殖及炎症反应的机制
张丽1,王艳青1,王艳1,刘建荣1,张晓敏2
字体:加大+|默认|缩小-
(1.山西医科大学第二医院皮肤科,山西 太原 030001;2.山西医科大学第二医院神经内科,山西 太原 030001)
摘要:
目的 替尔泊肽作为新型胰高血糖素样肽-1(GLP-1)/抑胃肽(GIP)双受体激动剂,其治疗潜力尚未在银屑病中得到阐明。本研究旨在探讨替尔泊肽对银屑病样角质形成细胞模型的影响及其作用机制。方法 首先,通过生物信息学分析筛选替尔泊肽的潜在作用靶点及通路。进而,采用M5细胞因子混合物刺激HaCaT细胞建立模型,设立对照组、模型组、替尔泊肽干预组及替尔泊肽联合FOXO1抑制剂组。通过CCK-8法评估细胞增殖活力,蛋白质印迹法检测FOXO1磷酸化水平与细胞周期蛋白D1(CCND1)表达,并对炎症反应相关指标进行检测。结果 生物信息学分析提示CCND1是关键靶点,并富集于FOXO信号通路。体外实验表明,替尔泊肽能有效抑制M5诱导的HaCaT细胞过度增殖,并减轻炎症反应。在机制上,替尔泊肽处理降低了p-FOXO1/FOXO1比值,同时下调了其下游靶点CCND1的蛋白表达。而FOXO1抑制剂则逆转了替尔泊肽的上述效应。结论 本研究提示,替尔泊肽可能通过FOXO1/CCND1信号通路,抑制角质形成细胞的异常增殖与炎症反应,从而为银屑病治疗提供了新的潜在策略与实验依据。
关键词:  替尔泊肽  FOXO1  细胞周期蛋白D1  银屑病  HaCaT细胞  炎症  网络药理学
DOI:10.13506/j.cnki.jpr.2026.09.004
基金项目:山西省高等学校科技创新项目(No.2022L156)
收稿日期:2026-03-02   修回日期:2026-05-14   出版日期:2026-09-30
Mechanism study of Tirzepatide inhibiting proliferation and inflammatory response in psoriatic HaCaT cells via the FOXO1/CCND1 signaling pathway
ZHANG Li1,WANG Yanqing1,WANG Yan1,LIU Jianrong1,ZHANG Xiaomin2
(1.Department of Dermatology, Second Hospital of Shanxi Medical University,Taiyuan 030001,China;2.Department of Neurology, Second Hospital of Shanxi Medical University, Taiyuan 030001,China)
Abstract:
Objective The therapeutic potential of tirzepatide, a novel GLP-1/GIP dual receptor agonist, has not been elucidated in psoriasis. This study aimed to investigate the effects of tirzepatide on a psoriasis-like keratinocyte model and its underlying mechanisms.Methods First, bioinformatics analysis was used to screen potential targets and pathways for tirzepatide. Subsequently, HaCaT cells were stimulated with an M5 cytokine mixture to establish a psoriasis-like keratinocyte model. Groups included a control group, a model group, a tirzepatide intervention group, and a tirzepatide combined with FOXO1 inhibitor group. Cell proliferation was assessed using the CCK-8 assay, FOXO1 phosphorylation levels and CCND1 protein expression were detected by Western blotting, and inflammatory markers were evaluated.Results Bioinformatics analysis indicated CCND1 as a key target enriched in the FOXO signaling pathway. In vitro experiments demonstrated that tirzepatide effectively suppressed M5-induced excessive proliferation in HaCaT cells and alleviated inflammatory responses. Mechanistically, tirzepatide treatment reduced the p-FOXO1/FOXO1 ratio while downregulating the protein expression of its downstream target CCND1. FOXO1 inhibitors reversed the aforementioned effects of tirzepatide.Conclusion This study suggests that tirzepatide may suppress abnormal proliferation and inflammatory responses in keratinocytes via the FOXO1/CCND1 signaling pathway, thereby providing a novel potential therapeutic strategy and experimental basis for psoriasis treatment.
Key words:  Tirzepatide  FOXO1  CCND1  Psoriasis  HaCaT  Inflammation  Network pharmacology
今日访问量:2274    总访问量:55338616
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司